We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





Low Testosterone Levels Tied to More Severe COVID in Men

By LabMedica International staff writers
Posted on 12 Sep 2022
Print article
Image: Blood sample for testosterone hormone test: Low Testosterone Levels Tied to More Severe COVID in Men (Photo courtesy of Rae Lynn Mitchell, MA)
Image: Blood sample for testosterone hormone test: Low Testosterone Levels Tied to More Severe COVID in Men (Photo courtesy of Rae Lynn Mitchell, MA)

The COVID-19 pandemic has exacted a heavy toll on public health. Male sex is associated with severe COVID-19. It is not known whether the risk of hospitalization differs between men with hypogonadism, men with eugonadism, and those receiving testosterone therapy (TTh).

Men with chronically low testosterone concentrations have decreased muscle mass and less strength, both of which contribute to reduced lung capacity and ventilator dependence. Pre–COVID-19 testosterone concentrations in men are associated with the course of illness after COVID-19 remains unknown.

A team of endocrinologists from the St Louis University School of Medicine (St Louis, MO; USA) and their colleagues conducted a cohort study in two large academic health systems in St Louis, among 723 men with a history of COVID-19 who had testosterone concentrations measured between January 1, 2017, and December 31, 2021. The team hypothesized that men with subnormal testosterone concentrations prior to COVID-19 infection would be more likely to require hospitalization than men with normal testosterone concentrations. They also investigated whether testosterone therapy (TTh) modified the risk of hospitalization among men with hypogonadism.

The testosterone concentrations measurements were performed using immunoassays for 441/723 (61%) of patients or by the criterion standard method, liquid chromatography tandem mass spectrometry for 282/723 (39%) of patients by commercial laboratories. The lower limit of normal for testosterone concentrations in the laboratories varied between 175 and 300 ng/dL. The upper limit ranged from 716 to 1,100 ng/dL. They defined hypogonadism as a total testosterone concentration below the lower limit of normal in the reference range provided by the laboratory.

The investigators reported that of the 723 study participants (mean ± SD age, 55 ±14 years; mean body mass index, 33.5 ±7.3), 116 men had hypogonadism, 427 had eugonadism, and 180 were receiving TTh. Men with hypogonadism were more likely than men with eugonadism to be hospitalized with COVID-19: 52/116 (45%) versus 53/427 (12%). After multivariable adjustment, men with hypogonadism had higher odds than men with eugonadism of being hospitalized (odds ratio, 2.4). Men receiving TTh had a similar risk of hospitalization as men with eugonadism (odds ratio, 1.3). Men receiving inadequate TTh (defined as subnormal testosterone concentrations while receiving TTh) had higher odds of hospitalization compared with men who had normal testosterone concentrations while receiving TTh (multivariable adjusted odds ratio, 3.5)

Sandeep Dhindsa, MD, an endocrinology specialist and co-author of the study, said, “Low testosterone turned out to be a risk factor for hospitalization from COVID, and treatment of low testosterone helped to negate that risk. The risk really increases when levels of testosterone in the blood are below 200 ng/dL. The normal range is 300 to 1,000 ng/dL. This is independent of all other risk factors that we looked at: age, obesity or other health conditions. But those people who were on therapy, their risk was normal.”

The authors concluded that the findings of this cohort study suggest that men with hypogonadism are more likely than men with eugonadism to be hospitalized after COVID-19 infection. They also suggest that men with hypogonadism who receive adequate TTh to achieve normal testosterone concentrations have a reduction in the risk of COVID-19–related hospitalization. The study was published on September 2, 2022 in the journal JAMA Network Open.

Related Links:
St Louis University School of Medicine 

Unit-Dose Twist-Tip BFS
Gold Supplier
COVID-19 Test Cassette
NG TEST COVID Immuni-T
New
3 Part Diff Auto Hematology Analyzer
HB7021
New
UHF RFID Tag and Inlay
AD-163u8

Print article

Channels

Molecular Diagnostics

view channel
Image: Medication, sepsis and inadequate blood supply to the kidneys are potential causes of AKI (Photo courtesy of Freepik)

Blood- And Urine-Based Biomarker Tests Could Identify Treatment of Acute Kidney Injury

Hospitalized patients who experience an acute kidney injury (AKI) often face unfavorable outcomes post-discharge, with limited effective treatment options. AKI can stem from various causes, such as sepsis,... Read more

Hematology

view channel
Image: The Atellica HEMA 570 and 580 hematology analyzers remove workflow barriers (Photo courtesy of Siemens)

Next-Gen Hematology Analyzers Eliminate Workflow Roadblocks and Achieve Fast Throughput

Hematology testing is a critical aspect of patient care, utilized to establish a patient's health baseline, track treatment progress, or guide timely modifications to care. However, increasing constraints... Read more

Immunology

view channel
Image: The first ever diagnostic test accurately predicts patient response to immunotherapy (Photo courtesy of Cofactor)

Immunotherapy Predictive Test Could Spare Cancer Patients from Unnecessary Chemotherapy

In recent years, there has been a significant increase in clinical trials for new cancer drugs. However, only a select group of patients have found success with these newer immunotherapies, which utilize... Read more

Microbiology

view channel
Image: New method reveals bacterial reaction to antibiotics within minutes (Photo courtesy of Freepik)

New Method to Reveal Bacterial Reaction to Antibiotics in Five Minutes Could Help Create Rapid Molecular Test

Severely sick patients suffering from bacterial infections often require immediate treatment to prevent serious health complications, making it vital for physicians to quickly identify the appropriate antibiotic.... Read more

Pathology

view channel
Image: navify digital solutions can helping labs mitigate unique quality challenges (Photo courtesy of Roche)

Cloud-Based Digital Solution Allows Labs to Track Test Samples along Entire Diagnostic Journey

Diagnosing a disease involves a meticulous procedure of monitoring a patient's diagnostic sample throughout its entire journey, which aids in clinical decision-making. However, there aren't any standardized... Read more

Technology

view channel
Electronic biosensor uses DNA aptamers for detecting biomarkers in whole blood samples (Photo courtesy of Freepik)

Electronic Biosensor Detects Biomarkers in Whole Blood Samples without Addition of Reagents

The absence of robust, reliable, and user-friendly bioanalytical tools for early and timely diagnosis of cardiovascular diseases, particularly sudden cardiac arrest, leads to preventable deaths and imposes... Read more

Industry

view channel
Image: The global hemostasis diagnostics market is expected to reach USD 3.95 billion by 2025 (Photo courtesy of Freepik)

Global Hemostasis Diagnostics Market Driven by Increase in Invasive Surgical Procedures

Injury or surgery naturally creates bleeding in living beings, which must be stopped to prevent excessive blood loss. The human body implements a protective mechanism known as hemostasis to stop excessive bleeding.... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.